SUPPLEMENTARY MATERIAL

PART A- SEARCH STRATEGY

Keywords

Search strategy for Embase.com (15.04.2020)

/exp = EMtree keyword with explosion
.tw = The Textword field in EMBASE includes Title (TI) and Abstract (AB).

Number	Search terms	Results
#1	exp plastic surgery/ OR exp surgeon/ OR exp plastic surgeon/ OR exp esthetic surgery/ OR exp skin transplantation/ OR exp microsurgery/ OR exp tissue flap/ OR exp Z plasty/ OR exp surgical flaps/ OR exp reconstructive surgery/ OR exp face surgery/ OR exp maxillofacial surgery/ OR exp oral surgery/ OR skin graft*.tw. OR full thickness graft*.tw. OR SSG.tw. or FTG.tw OR axial flap*.tw. OR pedicled flap*.tw. OR surgical flap*.tw. OR contracture release*.tw. OR exp free tissue graft/ OR free flap*.tw. OR regional flap*.tw. OR exp skin flap/ OR local flap*.tw. OR surger*.tw. OR surgical*.tw. OR operation*.tw. OR operative*.tw. OR incisi*.tw. OR excisi*.tw. OR management*.tw. OR treatment.tw	8557452
#2	Exp Vincent stomatitis/ OR acute necrotizing ulcerative gingivitis.tw OR acute necrotising ulcerative gingivitis.tw OR acute ulcerative gintivitis.tw OR Noma.tw OR cancrum oris.tw	1401
#3	#1 AND #2	639
Limits: Publication prior to final search, April 15th, 2020		

Search strategy for MEDLINE (PubMed) (15.04.2020)

/exp = MEDLINE keyword with explosion/ Mesh terms
.tw = The Textword field in MEDLINE includes Title (TI) and Abstract (AB).

Number	Search terms	Results
#1	exp Reconstructive Surgical Procedures/ OR exp Surgery, Plastic/ OR exp Tissue Transplantation/ OR exp Surgical Flaps/ OR exp Skin Transplantation/ ORexp Free Tissue Flaps/ OR exp Microsurgery/ OR exp Surgery, Oral/ OR exp Surgical Procedures, Operative/ OR exp "Oral and Maxillofacial Surgeons"/ OR exp Surgeons/ OR skin graft*.tw. OR full thickness graft*.tw. OR SSG.tw. OR FTG.tw. OR axial flap*.tw.	8167413

	OR pedicle flap*.tw. OR pedicled flap*.tw. OR surgical flap*.tw. OR contracture release*.tw. OR free flap*.tw. OR regional flap*.tw. OR local flap*.tw. OR surger*.tw. OR surgical*.tw. OR operation*.tw. OR operative*.tw. OR incisi*.tw. OR excisi*.tw. OR management*.tw. OR treatment*.tw	
#2	exp Noma/ OR cancrum oris.tw. OR exp Gingivitis, Necrotizing Ulcerative/ OR acute necrotizing ulcerative gingivitis.tw. OR acute necrotising ulcerative gingivitis.tw.	1664
#3	#1 AND #2	568
Limits: Publication prior to final search, April 15th, 2020		

Search strategy for Clarivate Analytics/Web of Science (15.04.2020)

TOPIC = words in title, abstract or keywords
ndexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, BKCI-S, BKCI-SSH, ESCI, CCR-EXPANDED, IC Timespan=All years

Number	**Search terms**	**Results**
#1	TS= (surger* OR surgical* OR surgeon* OR operation* OR operative* OR incisi* OR extracti* OR excisi* OR management* OR treatment*)	9,621,445
#2	TS= (reconstructi* OR cosmetic* OR esthetic* OR aesthetic* OR plastic OR corrective* OR oral* or *maxillofacial* OR facial OR face* OR "head and neck" OR flap* OR skin* or micro*)	8,095,337
#3	TS= (Noma OR "cancrum oris" OR "necrotizing ulcerative gingivitis" OR "acute necrotizing ulcerative gingivitis" OR "acute necrotising ulcerative gingivitis")	3,515
#4	#2 AND #1	1,821,209
#5	#4 AND #3	186
Limits: Publication prior to final search, April 15th, 2020		

Inclusion/exclusion criteria

Inclusion Criteria
1. Original publications 2. Human subjects 3. Case Series, Retrospective Data Analyses, Clinical Trials, Controlled Clinical Trials, Prospective Studies

Speiser S, *et al. BMJ Open* 2021; 11:e046303. doi: 10.1136/bmjopen-2020-046303

Exclusion Criteria
1. Publication type does not match inclusion criteria (Review articles, Mixed methodology studies without subgroup data, Animal studies, Conference Articles) 2. Conditions other than Noma, Cancrum Oris, or Necrotizing Ulcerative Stomatitis not related to Noma 3. The paper is about conditions located at sites other than the Maxillofacial and Head and Neck region 4. The paper is not about treatment 5. The paper is not about a surgical intervention (but included if terms such as reconstruction or rehabilitation, or flap or graft, are mentioned). 6. The paper is about prevention rather than treatment of Noma 7. The paper is written in a language other than German or English

Speiser S, *et al. BMJ Open* 2021; 11:e046303. doi: 10.1136/bmjopen-2020-046303

PART B- MINORS CRITERIA

Level of Evidence	**Types of Studies**
I	SR (with homogeneity) of RCTs, Individual RCT (with narrow Confidence Interval),
II	SR (with homogeneity) of cohort studies, Individual cohort study (including low quality RCT; e.g., <80% follow-up), "Outcomes" Research; Ecological studie
III	SR (with homogeneity*) of case-control studies, Individual Case-Control Study
IV	Case-series (and poor-quality cohort and case-control studies)
V	Expert opinion without explicit critical appraisal, or based on physiology, bench research or "first principles"

MINORS criteria
1. A clearly stated aim: the question addressed should be precise and relevant in the light of available literature
2. Inclusion of consecutive patients: all patients potentially fit for inclusion (satisfying the criteria for inclusion) have been included in the study during the study period (no exclusion or details about the reasons for exclusion)
3. Prospective collection of data: data were collected according to a protocol established before the beginning of the study
4. Endpoints appropriate to the aim of the study: unambiguous explanation of the criteria used to evaluate the main outcome which should be in accordance with the question addressed by the study. Also, the endpoints should be assessed on an intention-to-treat basis.
5. Unbiased assessment of the study endpoint: blind evaluation of objective endpoints and double-blind evaluation of subjective endpoints. Otherwise the reasons for not blinding should be stated
6. Follow-up period appropriate to the aim of the study: the follow-up should be sufficiently long to allow the assessment of the main endpoint and possible adverse events
7. Loss to follow up less than 5%: all patients should be included in the follow up. Otherwise, the proportion lost to follow up should not exceed the proportion experiencing the major endpoint
8. Prospective calculation of the study size: information of the size of detectable difference of interest with a calculation of 95% confidence interval, according to the expected incidence of the outcome event, and information about the level for statistical significance and estimates of power when comparing the outcomes
Additional criteria in the case of comparative study
9. An adequate control group: having a gold standard diagnostic test or therapeutic intervention recognized as the optimal intervention according to the available published data
10. Contemporary groups: control and studied group should be managed during the same time period (no historical comparison)

Speiser S, *et al. BMJ Open* 2021; 11:e046303. doi: 10.1136/bmjopen-2020-046303

11. Baseline equivalence of groups: the groups should be similar regarding the criteria other than the studied endpoints. Absence of confounding factors that could bias the interpretation of the results
12. Adequate statistical analyses: whether the statistics were in accordance with the type of study with calculation of confidence intervals or relative risk

Speiser S, *et al. BMJ Open* 2021; 11:e046303. doi: 10.1136/bmjopen-2020-046303

PART C- PRISMA FLOW CHART



Speiser S, *et al. BMJ Open* 2021; 11:e046303. doi: 10.1136/bmjopen-2020-046303

PART D- MINORS CRITERIA FOR INCLUDED STUDIES

First Author	Year	Type	Level of Evidence	1	2	3	4	5	6	7	8	9	10	11	12	Total	%
Adams-ray	1992	case series (RS)	4	1	1	0	1	0	0	1	0					4	50%
Adekeye	1983	case series (RS)	4	1	1	0	1	0	0	0	0					3	38%
Adekeye	1986	case series (RS)	4	1	0	0	1	0	0	1	0					3	38%
Bisseling	2010	case series (RS)	4	1	1	0	1	1	1	0	1					6	75%
Bouman	2010	case series (PS)	4	1	1	1	1	0	1	1	0					6	75%
Chidzonga	2008	case series (RS)	4	1	1	0	0	0	0	0	0					2	25%
Dammer	2005	case series (PS)	4	1	1	1	1	0	1	0	0					5	63%
Erdmann	1998	case series (RS)	4	1	1	1	0	0	0	0	0					3	38%
Giessler	2003	case series (RS)	4	0	1	0	0	0	1	0	0					2	25%
Giessler	2005	case series (RS)	4	1	1	0	0	0	0	0	0					2	25%
Giessler	2007	case series (RS)	4	0	1	0	0	0	0	0	0					1	13%
Giessler	2011	case series (RS)	4	1	0	0	0	0	0	0	0					1	13%
Hartman	2006	case series (RS)	4	1	0	0	0	0	0	0	0					1	13%
Heitland	2004	case series (RS)	4	1	1	1	1	0	0	0	0					4	50%
Holle	2020	case series (RS)	4	1	1	0	1	1	1	0	0					5	63%
Holle J.	2009	case series (RS)	4	1	1	0	1	1	1	1	0					6	75%
Honeyman	2019	cohort study (RS)	3	1	1	1	1	1	1	1	0	0	0	0	1	8	67%
Huijing	2011	cohort study (PS)	3	1	1	1	1	0	1	0	0	0	0	0	1	6	50%
Kuehnel	2003	case series (PS)	4	1	1	1	0	0	1	1	0					5	63%
Marck	1998	case series (PS)	4	0	1	1	0	0	0	0	0					2	25%
Montandon	1991	case series (RS)	4	0	1	0	0	0	0	0	0					1	13%
Nath	1997	case series (RS)	4	1	1	0	1	1	1	1	0					6	75%
Oluwasanmi	1976	case series (RS)	4	1	1	1	1	0	0	1	0					5	63%
Pittet	2001	case series (RS)	4	1	1	1	0	0	1	1	0					5	63%
Rodgers	2015	case series (RS)	4	1	1	1	1	0	0	0	0	0	0	0	0	4	50%
Rüegg	2016	case series (RS)	4	1	1	0	1	0	1	1						5	63%
Ruegg	2018	case series (RS)	4	1	1	0	1	0	1	1	0					5	63%
Saleh	2013	case series (RS)	4	1	1	1	1	0	0	0	0					4	50%
Shaye	2018	case series (RS)	4	1	1	0	0	0	0	0	0					2	25%
Simon	2015	case series (RS)	4	1	1	1	1	0	0	0	0					4	50%
Vinzenz	2008	case series (RS)	4	1	1	0	1	0	1	1	0					5	63%

Speiser S, *et al. BMJ Open* 2021; 11:e046303. doi: 10.1136/bmjopen-2020-046303

This page is intentionally left blank.